Abbott Laboratories (NY:ABT)

106.20 +1.63 (+1.56%)

Official Closing Price Updated: 7:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Abbott Laboratories

< Previous 1 2 3 4 5 6 Next >

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Northfield Bancorp Inc. (Nasdaq - NFBK), Coterra Energy Inc. (NYSE - CTRA), Exact Sciences Corporation (Nasdaq – EXAS), Semrush Holdings, Inc. (NYSE – SEMR)

February 09, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

February 03, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Abbott Laboratories (NYSE: ABT) Records 52-Week High Friday Morning

February 23, 2024

Via Investor Brand Network

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Exact Sciences Corporation (Nasdaq – EXAS)

November 20, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity

July 15, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ABT),(NASDAQ:DXCM),(NASDAQ:IRTC),(NASDAQ:TNDM) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)

May 13, 2025

Via Get News

Topics Death Economy

“Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”

December 06, 2024

Via AB Newswire

MarketBeat Week in Review – 10/14 - 10/18

October 19, 2024

Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.

Via MarketBeat

Topics Artificial Intelligence Economy

Abbott’s Growth and Dividends Make It a Smart Portfolio Pick

October 16, 2024

Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results align with the trend.

Via MarketBeat

Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns

September 17, 2024

These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025.

Via MarketBeat

Topics Economy

Medtronic Stock: Growth On Rise of the Cardiovascular Machines

September 09, 2024

Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases

Via MarketBeat

Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally

August 23, 2024

Medtronic's Q1 FY2025 results were driven by its diabetes products, and new offerings in development or pending FDA approval could fuel future performance.

Via MarketBeat

As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

August 09, 2024

EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

Intuitive Surgical Stock Outperforms Market: Highs on the Horizon

July 22, 2024

Intuitive Surgical is an AI stock that you can buy and hold forever. Its business is health care; it makes profits, and health care is growing

Via MarketBeat

Topics Artificial Intelligence

Why This Leading Health Stock is a Buy No Matter the Market Move

July 18, 2024

Abbott's reliable dividend is more reliable than ever and is expected to continue growing at a high-single to low-double-digit CAGR.

Via MarketBeat

U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist

July 11, 2024

From Financial Buzz Media

Via GlobeNewswire

AbbVie Stock: A Perfect Dip for Investors to Buy

July 03, 2024

ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors

Via MarketBeat

Topics ETFs

Global Sports Nutrition Market Projected to Reach $78 Billion as Muscle Repair & Growth Becoming Vitally Important

May 21, 2024

EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:ABT),(NASDAQ:CELH),(NASDAQ:MNST),(NYSE:BRBR) EQNX::TICKER_END

Via FinancialNewsMedia

Global Sports Nutrition Market Projected to Reach $78 Billion as Muscle Repair & Growth Becoming Vitally Important

May 21, 2024

From FN Media Group LLC

Via GlobeNewswire

Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX

April 30, 2024

Via AB Newswire

Boston Scientific Bucks the Medtech Slow Down and Raises Outlook

April 30, 2024

Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook.

Via MarketBeat

Abbott Laboratories Outlook is Healthy: Buy the Dip

April 17, 2024

Abbott Laboratories had a steady quarter, producing growth, better-than-expected earnings, and raising the guidance. Analysts see the stock moving higher.

Via MarketBeat

Johnson & Johnson is as Cheap as it’s Going to Get

April 16, 2024

Johnson & Johnson raised its dividend for the 62nd consecutive year and has the power to continue raising the annual payout indefinitely.

Via MarketBeat

DexCom Stock Gains from GLP-1 Diabetic Users

April 02, 2024

DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People

Via MarketBeat

Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)

March 20, 2024

Via AB Newswire

Topics Death

Medtronic is a Dividend Aristocrat That Keeps Gaining

March 11, 2024

A strong earnings report backed by raised guidance adds to the allure of Medtronic stock, which is already a Dividend Aristocrat in the healthcare sector

Via MarketBeat

Are These 5 Undervalued Stocks Ready to Break Out?

March 08, 2024

Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.

Via MarketBeat

4 med tech stocks with improving prognosis for 2024

January 31, 2024

MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025.

Via MarketBeat

Abbott Laboratories on track for new highs in 2024

January 25, 2024

Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact.

Via MarketBeat

Johnson & Johnson's stock price is at a critical turning point

January 23, 2024

Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech.

Via MarketBeat

Topics Intellectual Property

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.